TARSUS PHARMACEUTICALS, INC. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
TARSUS PHARMACEUTICALS, INC. (TARS) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $23.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $15.70M.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $7.71M, a 574.30% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$30.54M.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $37.18M, a 533.54% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $6.91M, a 171.46% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was $2.54M, a 43.93% decline from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was $4.54M, a 452.62% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2022 was $821.00K, a 78.84% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $15.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $23.41M 10-Q · filed 2026-08-06 | -$7.13M derived: sum of 3 quarters · filed 2026-08-06 | $30.05M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $7.71M 10-Q · filed 2026-05-06 | -$22.82M derived: sum of 2 quarters · filed 2026-05-06 | $14.35M derived: sum of 3 quarters · filed 2026-05-06 | $13.48M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$30.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $6.64M derived: sum of 2 quarters · filed 2026-02-23 | $5.76M derived: sum of 3 quarters · filed 2026-08-06 | $6.91M 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $37.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $36.30M derived: sum of 2 quarters · filed 2026-08-06 | $37.45M 10-Q · filed 2025-11-04 | $14.70M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$875.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $269.00K 10-Q · filed 2026-08-06 | $13.60M 10-Q · filed 2025-08-06 | -$22.48M derived: sum of 3 quarters · filed 2026-08-06 | -$16.61M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $1.14M 10-Q · filed 2026-05-06 | $11.31M 10-Q · filed 2025-05-01 | -$21.60M derived: sum of 2 quarters · filed 2026-05-06 | -$15.73M derived: sum of 3 quarters · filed 2026-05-06 | -$8.65M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | -$22.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$16.88M derived: sum of 2 quarters · filed 2026-02-23 | -$9.79M derived: sum of 3 quarters · filed 2026-02-23 | $2.54M 10-K · filed 2026-02-23 | $40.34M 10-K · filed 2025-02-25 | ||
| 2024-09-30 | $5.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $12.96M derived: sum of 2 quarters · filed 2025-11-04 | $25.29M 10-Q · filed 2025-11-04 | $24.65M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-06-30 | $7.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $19.42M 10-Q · filed 2025-08-06 | $18.78M derived: sum of 3 quarters · filed 2026-02-23 | $24.60M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-03-31 | $12.34M 10-Q · filed 2025-05-01 | $11.70M derived: sum of 2 quarters · filed 2026-02-23 | $17.51M derived: sum of 3 quarters · filed 2026-02-23 | $17.92M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2023-12-31 | -$640.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $5.17M derived: sum of 2 quarters · filed 2026-02-23 | $5.58M derived: sum of 3 quarters · filed 2026-02-23 | $4.54M 10-K · filed 2026-02-23 | $13.24M 10-K · filed 2024-02-27 | ||
| 2023-09-30 | $5.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $6.22M derived: sum of 2 quarters · filed 2024-11-13 | $5.18M 10-Q · filed 2024-11-13 | $4.81M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-06-30 | $409.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$637.00K 10-Q · filed 2024-08-08 | -$1.00M derived: sum of 3 quarters · filed 2025-02-25 | $319.00K derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-03-31 | -$1.05M 10-Q · filed 2024-05-08 | -$1.41M derived: sum of 2 quarters · filed 2025-02-25 | -$90.00K derived: sum of 3 quarters · filed 2025-02-25 | -$2.19M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2022-12-31 | -$366.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $956.00K derived: sum of 2 quarters · filed 2025-02-25 | -$1.15M derived: sum of 3 quarters · filed 2025-02-25 | $821.00K 10-K · filed 2025-02-25 | |||
| 2022-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$782.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.19M 10-Q · filed 2023-11-09 | $1.54M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | -$2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$135.00K 10-Q · filed 2023-08-10 | $222.00K derived: sum of 3 quarters · filed 2023-08-10 | -$877.00K derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $1.97M 10-Q · filed 2023-05-09 | $2.33M derived: sum of 2 quarters · filed 2023-05-09 | $1.23M derived: sum of 3 quarters · filed 2023-05-09 | $786.00K derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$742.00K derived: sum of 2 quarters · filed 2023-03-17 | -$1.18M derived: sum of 3 quarters · filed 2023-03-17 | $3.88M 10-K · filed 2023-03-17 | |||
| 2021-09-30 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$1.54M derived: sum of 2 quarters · filed 2022-11-09 | $3.52M 10-Q · filed 2022-11-09 | $3.74M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | -$441.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $4.62M 10-Q · filed 2022-08-11 | $4.84M derived: sum of 3 quarters · filed 2022-08-11 | $5.91M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $5.06M 10-Q · filed 2022-05-11 | $5.28M derived: sum of 2 quarters · filed 2022-05-11 | $6.35M derived: sum of 3 quarters · filed 2022-05-11 | $7.99M derived: sum of 4 quarters · filed 2022-05-11 | |||
| 2020-12-31 | $215.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $1.29M derived: sum of 2 quarters · filed 2022-03-14 | $2.93M derived: sum of 3 quarters · filed 2022-03-14 | $3.24M 10-K · filed 2022-03-14 | |||
| 2020-09-30 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $2.71M derived: sum of 2 quarters · filed 2021-11-10 | $3.02M 10-Q · filed 2021-11-10 | $3.01M derived: sum of 4 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.95M 10-Q · filed 2021-08-05 | $1.94M derived: sum of 3 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $313.00K 10-Q · filed 2021-05-11 | $302.00K derived: sum of 2 quarters · filed 2021-05-11 | |||||
| 2019-12-31 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $245.00K 10-K · filed 2021-03-31 | |||||
| 2019-09-30 | $256.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |